Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trial.
Yan M, Ouyang Q, Sun T, Niu L, Yang J, Li L, Song Y, Hao C, Chen Z, Liu Z, Lv H, Zhang M, Liu L, Yang X, Xiao H, Gao Z, Li X, Dong F, Zhang L, Dong D, Chen X, Qiao J, Zhang G, Zeng H, Wang J, Sun H, Feng Y, Chen Y, Xia F.
Yan M, et al. Among authors: dong d, dong f.
EClinicalMedicine. 2024 Sep 20;76:102837. doi: 10.1016/j.eclinm.2024.102837. eCollection 2024 Oct.
EClinicalMedicine. 2024.
PMID: 39380967
Free PMC article.